[Glucocorticoid-induced osteoporosis].
Prolonged glucocorticoids administration is the most common cause of secondary osteoporosis. It is estimated that 30% to 50% of chronic glucocorticoids users experience vertebral or hip fractures. The highest bone loss (up to 30% in some studies) is observed in the first six months of treatment. Only a minority of patients who take chronic glucocorticoids receive optimal osteoporosis diagnosis, prevention, and/or treatment. The aim of this paper is to present the pathophysiology of glucocorticoid-induced osteoporosis, as well as some guidelines on diagnostic, preventive and therapeutic strategies for this disorder in an effort to promote the greater awareness of it.
Foltyn
Wanda
W
Klinika Endokrynologii, Katedra Patofizjologii i Endokrynologii w Zabrzu, Slaska Akademia Medyczna, Katowice. wandafoltyn@poczta.onet.pl
Kos-Kudła
Beata
B
Marek
Bogdan
B
Kajdaniuk
Dariusz
D
Głogowska-Szelag
Joanna
J
Siemińska
Lucyna
L
Strzelczyk
Janusz
J
Borowska
Małgorzata
M
D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001862:Bone Resorption / Q000139:chemically induced; D001842:Bone and Bones / Q000378:metabolism; D002118:Calcium / Q000032:analysis*; D002454:Cell Differentiation / Q000187:drug effects; D050723:Fractures, Bone / Q000209:etiology*; D005938:Glucocorticoids / Q000009:adverse effects* / Q000627:therapeutic use; D006620:Hip Fractures; D006801:Humans; D010024:Osteoporosis / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy*
D050071:Bone Density Conservation Agents; D005938:Glucocorticoids; D002118:Calcium